In addition to regulating the viral RNA response activities of RIG-I and MDA5, LGP2 expression affects many other cellular processes, including CD8+ T cell survival, conferring cancer cells radioresistant or sensitive to ionizing radiation therapy depending on where LGP2 is expressed, and inhibiting the Dicer-mediated interference (RNAi) pathway (20,21). Here, DHX58 is linked to cancer.